Real-world outcomes with first-line ibrutinib (Ibr) versus chemoimmunotherapy (CIT) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the InformCLL registry Meeting Abstract
| Authors: | Ghosh, N.; Sharman, J. P.; Barrientos, J. C.; Brander, D.; Gutierrez, M.; Wu, L.; Qureshi, Z. P.; Upasani, S.; Naganuma, M.; Mato, A. R. |
| Abstract Title: | Real-world outcomes with first-line ibrutinib (Ibr) versus chemoimmunotherapy (CIT) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Final analysis results from the InformCLL registry |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 7047 |
| End Page: | 7049 |
| Language: | English |
| ACCESSION: | WOS:000893230300022 |
| DOI: | 10.1182/blood-2022-155649 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
